Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

Metsera has technologies and drug candidates intended to improve on these limitations. With key clinical trial readouts expected this year, the company took its story to investors through an IPO.

At the closing bell, Metsera’s stock MTSR stood at $26.50, well above its IPO pricing level of $18. It opened on the Nasdaq ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

The GLP-1 IPO arena has been heating up for the past two years and Metsera’s ask is one the largest in recent history.

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. | Obesity biotech Metsera and ...

Biotech company Metsera, which develops weight-loss drugs and is backed by ARCH Venture Partners, said on Monday that it is ...

Metsera Inc. is seeking to raise $292 million in an initial public offering, joining a clutch of health-care firms set to ...

Metsera, Inc MTSR IPO will take place January, 31 on the NASDAQ exchange under the ticker MTSR. The company is offering shares at an expected price between $15.00 and $17.00 per share with an insider ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...